Androgen Deprivation Therapy for Advanced Prostate Cancer: Can Evolution Be Accelerated?

被引：1

作者：

Mohler, James L. ^{[1
,2
,3
,4
,5
,6
,7
,8
]}

机构：

[1] Roswell Pk Canc Inst, Translat Res, Buffalo, NY 14263 USA

[2] Roswell Pk Canc Inst, Dept Urol, Buffalo, NY 14263 USA

[3] Roswell Pk Canc Inst, Prostate Program, Buffalo, NY 14263 USA

[4] Roswell Pk Canc Inst, Oncol, Buffalo, NY 14263 USA

[5] Univ Buffalo, Urol, Sch Med & Biomed Sci, Buffalo, NY USA

[6] Univ N Carolina, Urol, Chapel Hill, NC 27515 USA

[7] Johns Hopkins Univ, Sch Med, Urol Oncol, Baltimore, MD 21218 USA

[8] NCCN Guidelines Panel Prostate Canc, Buffalo, NY USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2016年 / 14卷 / 06期

关键词：

PELVIC LYMPHADENECTOMY; RADICAL PROSTATECTOMY; INTERMITTENT; IMMEDIATE;

D O I：

10.6004/jnccn.2016.0071

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：701 / 703

页数：3

共 50 条

[31] Evolution of androgen receptor targeted therapy for advanced prostate cancer
Yien Ning Sophia Wong
Roberta Ferraldeschi
Gerhardt Attard
Johann de Bono
Nature Reviews Clinical Oncology, 2014, 11 : 365 - 376
[32] Evolution of androgen receptor targeted therapy for advanced prostate cancer
Wong, Yien Ning Sophia
Ferraldeschi, Roberta
Attard, Gerhardt
de Bono, Johann
NATURE REVIEWS CLINICAL ONCOLOGY, 2014, 11 (06) : 365 - 376
[33] Androgen deprivation therapy in advanced prostate cancer: is intermittent therapy the new standard of care?
Klotz, L.
Toren, P.
CURRENT ONCOLOGY, 2012, 19 : S13 - S21
[34] What is the role of androgen deprivation therapy in the treatment of locally advanced prostate cancer?
Kollmeier, Marisa A.
Zelefsky, Michael J.
NATURE CLINICAL PRACTICE UROLOGY, 2008, 5 (11): : 584 - 585
[35] Re: Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
不详
JOURNAL OF UROLOGY, 2021, 205 (01): : 303 - 304
[36] Sexual Bother in Men with Advanced Prostate Cancer Undergoing Androgen Deprivation Therapy
Benedict, Catherine
Traeger, Lara
Dahn, Jason R.
Antoni, Michael
Zhou, Eric S.
Bustillo, Natalie
Penedo, Frank J.
JOURNAL OF SEXUAL MEDICINE, 2014, 11 (10): : 2571 - 2580
[37] Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer
Saad, Fred
Shore, Neal D.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
[38] Interferon signaling confers resistance to androgen deprivation therapy in advanced prostate cancer
Agarwal, Supreet
McGowen, Kerry
Elloumi, Fathi
Cam, Maggie
Beshiri, Mike
Jansson, Keith
Corey, Eva
Kelly, Kathleen
CANCER RESEARCH, 2018, 78 (13)
[39] Re: Oral Relugolix for Androgen-deprivation Therapy in Advanced Prostate Cancer
Chow, Alexander K.
Vourganti, Srinivas
Konety, Badrinath R.
EUROPEAN UROLOGY, 2021, 80 (03) : 386 - 386
[40] CARDIOVASCULAR RISK FACTORS FOR PATIENTS WITH ADVANCED PROSTATE CANCER ON ANDROGEN DEPRIVATION THERAPY
Gan, Zoe
Chelluri, Raju
Xia, Leilei
Fombona, Anisleidy
Guzzo, Thomas
Lee, Daniel
JOURNAL OF UROLOGY, 2020, 203 : E178 - E179

← 1 2 3 4 5 →